Management Change/Compensation Form 8 K

(a)

On January 10, 2025, Eric Bjerkholt tendered his resignation as a member of the board of directors (the "Board") of CalciMedica, Inc., a Delaware corporation (the "Company") and as Chair and a member of the audit committee of the Board, effective as of January 15, 2025 (the "Effective Date").

Mr. Bjerkholt's resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies, practices or otherwise.

(d)

On January 13, 2025, the Company's Board appointed Alan Glicklich, M.D., as a Class I director of the Company, effective as of the Effective Date, with a term of office expiring at the 2027 annual meeting of stockholders. There are no arrangements or understandings between Dr. Glicklich and any other person pursuant to which he was selected as a director. In addition, there are no transactions in which Dr. Glicklich has an interest that would require disclosure under Item 404(a) of Regulation S-K.

Pursuant to the Company's compensation policy for non-employee directors(the "Compensation Policy"), Dr. Glicklich (i) will receive an annual cash retainer of $40,000 for service as a member of the Board, pro-ratedbased on days served, and (ii) will be granted on the Effective Date an option to purchase 20,000 shares of the Company's common stock, which vests monthly over a three-year period from the date of grant, subject to Dr. Glicklich's continuous service. Dr. Glicklich will enter into the Company's standard form of Indemnity Agreement for directors of the Company, a copy of which is filed as Exhibit 10.1 to the Company's Registration Statement on Form S-1,filed with the SEC on September 4, 2020.